Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

@article{Arijs2009MucosalGS,
  title={Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.},
  author={Ingrid Arijs and Kai Li and Gary Toedter and Roel Quintens and Leentje van Lommel and Kristel Van Steen and Peter Leemans and Gert de Hertogh and Katleen Lemaire and Martina Ferrante and Fabian Schnitzler and Lieven Thorrez and Ke Ma and X. Song and Caterina Marano and Gert Van Assche and S{\'e}verine Vermeire and Karl Geboes and Frans Schuit and Fr{\'e}d{\'e}ric Baribaud and P. R. Rutgeerts},
  journal={Gut},
  year={2009},
  volume={58 12},
  pages={1612-9}
}
BACKGROUND AND AIMS Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. METHODS Two cohorts of patients who received their first treatment with infliximab for refractory… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 94 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…